Why our partnership makes a difference
When tested with SPEP alone,
1 in 8 patients may be missed3
Impact of a early and accurate diagnosis
Early suspicion of multiple myeloma in the primary care setting can enable earlier diagnosis and treatment. Together, we can empower primary care providers to detect this blood cancer early and improve patient outcomes.
Enable primary care providers to better help their patients by:
Behind every test result is a patient counting on us to get it right.
What you get as a Binding Site partner
As a Binding Site partner, you’ll get access to customizable, ready-to-use campaigns tailored to your audience—designed to raise myeloma awareness, drive appropriate testing, keep clinicians informed, and ultimately improve patient care and increase lab revenue—all at no cost to you.
Here's what's inside the Binding Site partner library:
We share a mission and want to help you impact patients’ lives
The significant testing gap for multiple myeloma is cause for concern5. By ordering sFLC alongside SPEP and IFE, we increase diagnostic sensitivity to >99%, helping ensure that patients aren't missed. We believe in empowering healthcare providers to identify multiple myeloma early, facilitating prompt diagnosis and intervention by a hematologist
Guideline-recommended testing is better for patients, primary care providers, and your business.
Learn how a Binding Site Partnership can help you work more effectively with healthcare providers, amplify your message, and succeed.
Together, we can make an even bigger impact.
Complete this form and we will get back to you
References
- Genzen JR, Murray DL, Abel G, et al. Screening and Diagnosis of Monoclonal Gammopathies: An International Survey of Laboratory Practice. Arch Pathol Lab Med. 2018;142(4):507-515.
- Mikhael J, Bhutani M, Cole CE. Multiple Myeloma for the Primary Care Provider: A Practical Review to Promote Earlier Diagnosis Among Diverse Populations. Am J Med. 2023;136(1):33-41.
- Internal data. US Primary Care provider survey, Fielded by Bioinformatics, Inc. between Oct-Dec 2024, Data Analysis by Binding Site, part of Thermo Fisher Scientific.
- Katzmann JA, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem. 2009 Aug;55(8):1517-22
- Genzen JR, Murray DL, Abel G, et al. Screening and Diagnosis of Monoclonal Gammopathies: An International Survey of Laboratory Practice. Arch Pathol Lab Med. 2018;142(4):507-515.